The short version of Preclinical research fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-30 and is reviewed periodically as new material appears.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
| Property | Value | Notes |
|---|---|---|
| Primary proposed target | HGF/c-Met signaling | Direct binding not confirmed |
| Research models | Rodent and cell studies | Preclinical only |
| Human clinical data | None published | Safety and efficacy unknown |
| Regulatory status | Unapproved research chemical | Status varies by country |
| Typical research purity | 95% or higher by HPLC | Depends on supplier and batch |
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
=== New ownership === In December 2017, Patrick Cryne and his family sold an 80% stake in the club to NewCity Capital's Chien Lee and Pacific Media Group's Paul Conway. They were joined by Indian investor Neerav Parekh and Billy Beane, minority owner of and advisor for the Athletics, who was widely known for the Moneyball film portrayal, as part of an international investor consortium. Barnsley were relegated to the third tier in 2017–18. Following this, the new owners adopted a data-driven approach to identify talents, focusing on young players and team rebuilding. The club appointed Daniel Stendel as head coach, who introduced a high-pressing style of play. Barnsley were promoted back to the Championship the following season. In the 2019–20 season, under new coach Gerhard Struber, Barnsley avoided relegation from the Championship. In 2020–21, under the management of Valérien Ismaël, Barnsley finished fifth place and reached the EFL Championship Play-offs for the first time in 24 years, doing so with the youngest squad and one of the smallest budgets in the division. The Wall Street Journal called Barnsley a "Moneyball experiment". Prior to the 2021–22 season, Markus Schopp was appointed as the new head coach. In November 2021, he was dismissed after seven consecutive defeats. Three weeks later Poya Asbaghi was appointed as his successor. Fortunes improved little as Barnsley were relegated from the 2021–22 EFL Championship following a 2–1 defeat against Huddersfield Town. Asbaghi left the club by mutual consent shortly afterwards.
Thomas Lectka is an American organic chemist, academic and researcher. He is Jean and Norman Scowe Professor of Chemistry and leads the Lectka Group at Johns Hopkins University. Lectka specializes in areas of catalysis in synthetic and mechanistic organic chemistry and has authored over 120 research publications. He has made contributions in the discovery of metal-catalyzed amide isomerization; the development of first practical method for the catalytic, asymmetric synthesis of beta-lactams; the synthesis of [C-F-C] fluoronium ions; and site-selective aliphatic fluorination.
=== Prehistory === The site of modern-day Moscow has been inhabited since prehistoric times. Among the earliest archaeological discoveries were relics of the Lyalovo culture, which experts assign to the Neolithic period. These relics confirm that the area's first inhabitants were hunters and gatherers. Around 950 AD, two Slavic tribes—Vyatichi and Krivichi—settled in the area. The Vyatichi may have formed the majority of Moscow's indigenous population.
Acupuncture, along with moxibustion, is one of the oldest practices of traditional Chinese medicine. Most historians believe the practice began in China, though there are some conflicting narratives on when it originated. Academics David Ramey and Paul Buell said the exact date acupuncture was founded depends on the extent to which dating of ancient texts can be trusted and the interpretation of what constitutes acupuncture. Acupressure therapy was prevalent in India. Once Buddhism spread to China, the acupressure therapy was also integrated into common medical practice in China and it came to be known as acupuncture. The major points of Indian acupressure and Chinese acupuncture are similar to each other. According to an article in Rheumatology, the first documentation of an "organized system of diagnosis and treatment" for acupuncture was in Inner Classic of Huang Di (Huangdi Neijing) from about 100 BC. Gold and silver needles found in the tomb of Liu Sheng from around 100 BC are believed to be the earliest archaeological evidence of acupuncture, though it is unclear if that was their purpose. According to Plinio Prioreschi, the earliest known historical record of acupuncture is the Shiji ("Records of the Grand Historian"), written by a historian around 100 BC. It is believed that this text was documenting what was established practice at that time.
== Diagnosis == Laboratory investigations usually show elevated creatine kinase, myopathic/dystrophic muscle pathology and altered α-dystroglycan. Antenatal diagnosis is possible in families with known mutations. Prenatal ultrasound may be helpful for diagnosis in families where the molecular defect is unknown.
Sources: en.wikipedia.org
To ensure early detection, all individuals with MCTD must have screening echocardiography and high-resolution computed tomography upon diagnosis. Mild cases require regular testing to monitor for progression. Traditional therapies such as calcium channel blockers, ACE inhibitors, immunosuppression, and heart failure medications can be used. Pericarditis is typically treated with NSAIDs and/or corticosteroids based on severity. For moderate to severe myocarditis, high-dose steroid therapy should be combined with standard congestive heart failure treatment. Treatment for gastrointestinal problems in MCTD is identical to that for systemic sclerosis. First-line treatment for chronic reflux symptoms includes proton-pump inhibitors, H2-receptor antagonists, lifestyle changes, and oesophageal PH monitoring. Kidney involvement can lead to nephrotic syndrome, which may be treated with high-dose corticosteroid therapy. Corticosteroids are used to treat nervous system involvement in low-dose oral, high-dose oral, or high-dose intravenous regimens, depending on the severity of the potential harm.
=== Biosynthesis === Cannabinoid production begins with an enzyme combining geranyl pyrophosphate and olivetolic acid to form CBGA. CBGA is converted to THCA, CBDA, or CBCA by separate synthases, FAD-dependent dehydrogenase enzymes that diverged from a promiscuous common ancestor. There is no enzymatic conversion of CBDA or CBD to THCA or THC. Propyl homologues (CBGVA, THCVA, CBDVA, CBCVA) follow an analogous pathway from divarinolic acid.
Inside the nucleus, PIDD1 forms a complex with critical replication machinery components, including proliferating cell nuclear antigen (PCNA), replication factor C subunit 5 (RFC5), and RFC4, known collectively as the PCNA-PIDDosome. These proteins were identified as binding partners of overexpressed PIDD1 through mass spectrometry analysis. PCNA functions as a DNA sliding clamp that requires RFC for its correct placement on the DNA and is crucial for loading DNA polymerases during the replication process. Moreover, the activation of p53, which occurs in response to centrosome amplification—commonly resulting from failed cytokinesis—clearly relies on the Caspase-2−PIDDosome. Notably, PIDD1 seems to check the number of mature mother centrioles, though the specific mechanism by which it does so remains to be understood. Additionally, PIDD1 localizes to the distal end of mature centrosomes in healthy cells, indicating a possible role in centrosome function or stability.
=== Preclinical === EB-002 (EB-373; psilocin prodrug) – non-selective serotonin receptor agonist and psychedelic hallucinogen [16] Midomafetamine (MDMA; ecstasy) microneedle patch – serotonin–norepinephrine–dopamine releasing agent, weak serotonin 5-HT2 receptor agonist, and entactogen [17] Nerinetide (NA-1; Tat-NR2B9c) – PDZ domain inhibitor [18] OV-4041 – potassium–chloride-cotransporter agonist [19] PSIL-025 – serotonin 5-HT1 receptor modulator [20]
Sources: en.wikipedia.org
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.
No published human clinical trials are available for dihexa. Its safety and effectiveness in people are therefore unknown. Most available evidence comes from animal and cell studies.
Preclinical studies often measure dendritic spine density and synaptic protein levels. Behavioral tests include maze learning and avoidance tasks. These endpoints are indirect and do not establish clinical benefit.
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.